GlassScriptPhysician profile
Wesley L Davison
NPI 1801259924
$730.84
in general payments reported to CMS, 2019-2025
14 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.62 · 2022: $232 · 2023: $20.01 · 2024: $156 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $184.14 | 2022-2025 | |
| Stryker Corporation | $91.29 | 2022 | |
| Kaleo, INC. | $74.70 | 2022 | |
| Hikma Pharmaceuticals USA | $72.23 | 2024-2025 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $68.72 | 2025 | |
| Aerin Medical INC. | $41.69 | 2024 | |
| Glaxosmithkline, LLC. | $30.89 | 2025 | Nucala |
| Integra Lifesciences Corporation | $29.95 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Genzyme Corporation | $24.21 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.04 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.18 | 2025 | Xhance |
| Horizon Therapeutics Plc | $22.52 | 2022 | |
| Genentech USA, INC. | $21.70 | 2025 | Xolair |
| Merck Sharp & Dohme LLC | $21.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Davison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.